Brief: Acorda Therapeutics Announces New Agreement With Catalent For Long-Term Global Supply Of Inbrija®
05/01/2023 21:49
Jan 5 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS ANNOUNCES NEW AGREEMENT WITH CATALENT
FOR
LONG-TERM GLOBAL SUPPLY OF INBRIJA®
* ACORDA THERAPEUTICS INC - 2026 MANUFACTURING CAPACITY
EXPANSION
EXPECTED TO RESULT IN FURTHER REDUCTIONS IN COST OF GOODS
* ACORDA THERAPEUTICS INC - UNDER NEW SUPPLY AGREEMENT
ACORDA IS
REQUIRED TO PURCHASE $8.5 MILLION IN INBRIJA SUPPLY IN 2023 AND
$15.5 MILLION IN 2024
* ACORDA THERAPEUTICS INC - ACORDA WILL PAY AN $8 MILLION
TERMINATION FEE TO CATALENT IN CONNECTION WITH TERMINATION OF
PRIOR GLOBAL SUPPLY AGREEMENT
* ACORDA THERAPEUTICS INC - BEGINNING IN 2025, ACORDA WILL
PAY A
FIXED CAPSULE FEE BASED ON AMOUNT OF INBRIJA NEEDED IN US AND
OTHER MARKETS
* ACORDA THERAPEUTICS INC - BY 2026, AN EXPANSION IN
CATALENT'S
MANUFACTURING CAPACITY IS EXPECTED TO REDUCE PER-CAPSULE PRICES
SIGNIFICANTLY
Source text for Eikon: ID:nBw5hPXP3a
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease